Nothing Special   »   [go: up one dir, main page]

DK2707391T3 - Antistoffer mod her3 - Google Patents

Antistoffer mod her3 Download PDF

Info

Publication number
DK2707391T3
DK2707391T3 DK12719763.0T DK12719763T DK2707391T3 DK 2707391 T3 DK2707391 T3 DK 2707391T3 DK 12719763 T DK12719763 T DK 12719763T DK 2707391 T3 DK2707391 T3 DK 2707391T3
Authority
DK
Denmark
Prior art keywords
antibody
her3
seq
ser
gly
Prior art date
Application number
DK12719763.0T
Other languages
English (en)
Inventor
Abdelhakim Kharrat
Olivier Dubreuil
Yassamine Lazrek
Philippe Mondon
Khalil Bouayadi
Thierry Chardes
Andre Pelegrin
Christel Larbouret
Nadege A Gaborit
Original Assignee
Gamamabs Pharma
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamamabs Pharma, Inst Nat Sante Rech Med filed Critical Gamamabs Pharma
Application granted granted Critical
Publication of DK2707391T3 publication Critical patent/DK2707391T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Anti-HER3-antistof, som omfatter: - en tung kæde, hvor det variable domæne omfatter SEQ ID NO: 1 for H-CDR1, SEQ ID NO: 2 for H-CDR2 og SEQ ID NO: 3 for H- CDR3; og - en let kæde, hvor det variable domæne omfatter SEQ ID NO: 4 for L-CDR1, SEQ ID NO: 5 for L-CDR2 og SEQ ID NO: 6 for L- CDR3 .
2. Antistof ifølge krav 1, hvor det variable domæne af den tunge kæde har aminosyresekvensen ifølge SEQ ID NO: 7.
3. Antistof ifølge et hvilket som helst af kravene 1 eller 2, hvor det variable domæne af den lette kæde har aminosyresekvensen ifølge SEQ ID NO: 8.
4. Antistof ifølge et hvilket som helst af kravene 1-3, hvor antistoffet er valgt fra gruppen bestående af et antistof, som omfatter det variable domæne af en tung kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 7, og det variable domæne af en let kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 8.
5. Antistof ifølge et hvilket som helst af kravene 1-4, hvor antistoffet er et humant antistof.
6. Antistof ifølge et hvilket som helst af kravene 1-5, hvor antistoffet er et antistoffragment valgt fra gruppen bestående af Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2 og diabodies.
7. Farmaceutisk sammensætning, som omfatter et antistof ifølge et hvilket som helst af kravene 1-6 og en farmaceutisk acceptabel bærer.
8. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse som lægemiddel.
9. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse ved behandling af cancer.
DK12719763.0T 2011-05-13 2012-05-11 Antistoffer mod her3 DK2707391T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305583 2011-05-13
PCT/EP2012/058769 WO2012156309A1 (en) 2011-05-13 2012-05-11 Antibodies against her3

Publications (1)

Publication Number Publication Date
DK2707391T3 true DK2707391T3 (da) 2018-02-05

Family

ID=46046250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12719763.0T DK2707391T3 (da) 2011-05-13 2012-05-11 Antistoffer mod her3

Country Status (8)

Country Link
US (1) US9346883B2 (da)
EP (1) EP2707391B1 (da)
DK (1) DK2707391T3 (da)
ES (1) ES2657862T3 (da)
NO (1) NO2707391T3 (da)
PL (1) PL2707391T3 (da)
PT (1) PT2707391T (da)
WO (1) WO2012156309A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114883C2 (uk) 2010-08-20 2017-08-28 Новартіс Аг Антитіло до рецептора епідермального фактора росту-3 (her3)
EP2788381A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
CA2941077A1 (en) * 2014-02-28 2015-09-03 Merus N.V. Antibody that binds erbb-2 and erbb-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
CN111108123A (zh) * 2017-05-29 2020-05-05 加马玛布斯制药公司 癌症相关的免疫抑制抑制剂
CN118562014A (zh) 2017-08-09 2024-08-30 美勒斯公司 结合EGFR和cMET的抗体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1297172B1 (en) 2000-06-28 2005-11-09 Glycofi, Inc. Methods for producing modified glycoproteins
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PL2716301T3 (pl) 2007-02-16 2017-10-31 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants

Also Published As

Publication number Publication date
WO2012156309A1 (en) 2012-11-22
EP2707391A1 (en) 2014-03-19
EP2707391B1 (en) 2017-11-08
PL2707391T3 (pl) 2018-04-30
PT2707391T (pt) 2018-02-06
ES2657862T3 (es) 2018-03-07
US20140141019A1 (en) 2014-05-22
US9346883B2 (en) 2016-05-24
NO2707391T3 (da) 2018-04-07

Similar Documents

Publication Publication Date Title
DK2707391T3 (da) Antistoffer mod her3
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
CN112513095B (zh) Her3抗原结合分子
CN108424456B (zh) 特异于her3的结合分子及其用途
JP6120833B2 (ja) 抗Ａｘｌ抗体及びその使用
JP6033293B2 (ja) 抗Ａｘｌ抗体及びその使用
JP2022071071A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
EP3116911B1 (en) Anti-mcam (cd146, muc16) antibodies and associated methods of use
KR20210109520A (ko) 항체 및 이의 용도
KR20170070076A (ko) 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
TW200848428A (en) Novel antibodies
WO2015048008A2 (en) Binding molecules specific for her3 and uses thereof
JP2022500072A (ja) Ｎｔｓｒ１に特異的な抗体およびその使用
JP6449876B2 (ja) ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
EP2985292A1 (en) Epidermal growth factor receptor antibody
WO2023031435A9 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
EP3183342B1 (en) Method for prophylaxis and/or treatment of erbb1 positive cancers
WO2017072150A1 (en) Anti-nrg1 (heregulin) antibodies and uses thereof
NZ625046B2 (en) Binding molecules specific for her3 and uses thereof